TABLE 3.

Change from baseline in exploratory clinical endpoints at month 24.

			Continuersc
Adjusted change from baseline, mean (SE)	Placebo switchersa	1 to 3 mg/kgb	3 mg/kg	6 mg/kg	10 mg/kg	Titration
NTB overall z score	−0.40 (0.11) n = 28	−0.67 (0.14) n = 13	−0.29 (0.13) n = 16	−0.38 (0.13) n = 19	−0.24 (0.14) n = 15	−0.18 (0.14) n = 16
FCSRT sum of free recall score	−5.00 (1.36) n = 26	−5.46 (1.80) n = 14	−2.32 (1.78) n = 14	−6.52 (1.59) n = 21	0.03 (1.74) n = 15	−2.10 (1.86) n = 16
NPI‐Q total distress score	0.68 (0.93) n = 28	1.32 (1.24) n = 14	1.03 (1.15) n = 17	2.25 (1.11) n = 21	0.96 (1.22) n = 15	−0.29 (1.30) n = 16

Notes: Adjusted mean and SE for each treatment group were based on the MMRM. The MMRM was fitted with change from baseline as a dependent variable and included fixed effects for categorical treatment, categorical visit and treatment‐by‐visit interaction, continuous baseline value, and laboratory APOE status (carrier and noncarrier). The NTB includes the Rey Auditory Verbal Learning Test Immediate and Delayed Recall, Wechsler Memory Scale Verbal Pair Associate Learning Test Immediate and Delayed Recall, Delis‐Kaplan Executive Function System Verbal Fluency Conditions 1 and 2, and Wechsler Adult Intelligence Scale Fourth Edition Symbol Search and Coding Subsets.

Abbreviations: APOE ε4; apolipoprotein E ε4; FCSRT, Free and Cued Selective Reminding Test; LTE, long‐term extension; MMRM, mixed model for repeated measures; NPI‐Q, Neuropsychiatric Inventory Questionnaire; NTB, Neuropsychological Test Battery.

^a Placebo switchers received aducanumab 3 mg/kg or titration (3–6 mg/kg or 1–10 mg/kg) in the LTE.

^b Participants in the 1‐ to 3‐mg/kg arm received aducanumab 3 mg/kg in the LTE.

^c Participants who were randomized to receive 3, 6, or 10 mg/kg or titration were scheduled to continue the same dose throughout the LTE.